BACKGROUND The development of brain metastases is common for systemic treatment
failure in patients with melanoma and has been associated with a poor prognosis. Recent …

Background Historically, the prognosis for patients who have melanoma brain metastasis
(MBM) has been dismal. However, breakthroughs in targeted and immunotherapies have …

The successes of checkpoint blockade immunotherapy (CBI) and BRAFV600-targeted
therapy trials have generated substantial promise for revolutionizing the management of …

Background Melanoma brain metastasis is associated with an extremely poor prognosis,
with a median overall survival of 4–5 months. Since 2011, the overall survival of patients …

Opinion statement With greater understanding of underlying biology and development of
effective BRAF-targeted therapy and immunotherapy, along with remarkable advances in …

Background Treatment options for patients with melanoma brain metastasis (MBM) have
changed significantly in the last decade. Few studies have evaluated changes in outcomes …

Melanoma brain metastases (MBM) are common and associated with a particularly poor
prognosis; they directly cause death in 60–70% of melanoma patients. In the past, systemic …

Background The incidence of brain metastases (BM) in melanoma patients is common and
associated with poor prognosis. MAP-kinase inhibitors and immunologic checkpoint …

Abstract Background Melanoma brain metastases (MBMs) are historically associated with
poor prognosis. Radiation therapy is conventionally associated with a high local control rate …

Background Melanoma brain metastases (MBMs) are a challenging clinical problem with
high morbidity and mortality. Although first-line dabrafenib–trametinib and ipilimumab …